Added matter, Amendments, Case Law, Infringement, Litigation, Patents, Pharma, Pharmaceutical patent, Plausibility, Revocation, Sufficiency of disclosure, United Kingdom, Validity

, , (Bristows)/

On 21 March 2023, Meade J gave a bumper judgment in the revocation action brought by Gilead in respect of two of NuCana’s patents from the same family (EP (UK) 2 955 190 and EP (UK) 3 904 365, the “Patents”), which relate to nucleoside analogues.   Filling 102 pages, the judgment raises a number of…

Inventive step, Kluwer Patent Cases, Litigation, Patents, Prior art, Public prior use, Revocation, United Kingdom, Validity

, , (Bristows)/ /16 Comments

Mishan (T/A Emson) v Hozelock & Ors [2020] EWCA Civ 871 Since Arnold LJ’s elevation to the Court of Appeal in 2019, he and Floyd LJ have heard about 11 cases together, spanning a mixture of areas of law, some patents cases and some not.  In the majority of these cases, Floyd LJ (or a…

Case Law, Damages, Infringement, Injunction, Litigation, Pharma, Pharmaceutical patent, United Kingdom

(Bristows)/ /1 Comment

The tendency of English people to be understated in their use of language (other than on Twitter…) is often joked about with continental friends and colleagues.  For example, when an English person expresses a slight disagreement, their continental counterpart might have felt more able to be blunt and say that something is just plain wrong. …

EPO, Infringement, Injunction, Patents, Pharma, Pharmaceutical patent, Second Medical Use, United Kingdom

, (Bristows)/ /1 Comment

The English Patents Court has often been regarded as a relatively favourable jurisdiction for patentees seeking interim relief in the life sciences arena. This is for various reasons, including the fact that the English Court follows the approach adopted by the House of Lords in the American Cyanamid case, in which an assessment of the…

Antibodies, Biologics, Case Law, Damages, Infringement, Injunction, Litigation, United Kingdom, Validity

, (Bristows)/

Whilst being wary of placing too much emphasis on statistics (the phrase “lies, damn lies and statistics” comes to mind), the authors have seen figures which suggest that the last ten years have consistently seen English patent litigation outcomes which are overall less favourable to the patentee than their opponents. That is until 2017, when…

EPC, EPO, Equivalents, Inventive step, Litigation, Novelty, Pharma, Pharmaceutical patent, Prior art, Revocation, Second Medical Use, United Kingdom, Validity

(Bristows)/

Patent lawyers in the UK have spent the last three months pondering, debating and at times indulging in an element of despair (to put it mildly) about what might be the impact of the judgment of the Supreme Court in Actavis v Eli Lilly [2017] UKSC 48 on issues of validity (see here). Today they…

(Indirect) infringement, Pharma, Procedure, Revocation, Second Medical Use, Sufficiency of disclosure, United Kingdom, Validity

, , (Bristows)/

Media attention at the English High Court today may have been focussed on the Article 50 challenge but for many patent lawyers operating in the life sciences sector, of equal or greater importance was the handing down of the long-awaited judgment in the Lyrica appeal. To recap briefly, Pfizer was the owner of a patent…